While the use of ssODNs is limited to non-viral delivery methods, the application of these therapeutic molecules may initiate a direct and safe correction of point mutations within the ATP7B gene, thus contributing to a WD gene modification with high therapeutic potential in clinical application. The gene discussed is ATP7B; the disease is Wilson disease.